Position in DNLI
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$1,389,239
+$307,800 QoQ
Shares Held
54,014
-4.1% QoQ
Ownership
0.034%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#111
of 290 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 99%
Shared 0%
None 1%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Pathstone Holdings, LLC holds $101,065,916 across 56 Biotechnology names. DNLI ranks #22 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
45,952 | $22,825,735 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
13,825 | $8,620,440 | |
| 3 | ASND |
Ascendis Pharma A/S
|
20,248 | $5,400,545 | |
| 4 | CYTK |
Cytokinetics Inc
|
47,633 | $4,057,854 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
15,152 | $3,651,176 | |
| 6 | PTGX |
Protagonist Therapeutics, Inc
|
28,187 | $3,455,162 | |
| 7 | RPRX |
Royalty Pharma plc
|
54,725 | $3,068,429 | |
| 8 | ARGX |
Argenx SE
|
3,094 | $2,870,519 |
All Filings in DNLI
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,389,239 | 54,014 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $1,081,439 | 56,325 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $849,009 | 51,424 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $665,451 | 45,830 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $630,109 | 45,040 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $520,755 | 38,305 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $432,544 | 21,224 | Shares | Defined | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||